This pharmacological agent can inhibit TGF-β2-induced ECM expression by repressing MyD88/NF-κB signaling pathway in hTM cell (Li et al., 2023), showing that baicalin can be regarded as a potential candidate for glaucoma treatment. Here, TGFB2 is linked to glaucoma.